<DOC>
	<DOCNO>NCT03050229</DOCNO>
	<brief_summary>To explore beneficial effect 'empagliflozin + ARB ' comparison 'placebo + ARB ' reduction nocturnal blood pressure T2DM hypertension</brief_summary>
	<brief_title>SGLT-2i ARB Combination Therapy Patients With T2DM Nocturnal Hypertension ( SACRA Study )</brief_title>
	<detailed_description>The study consist 8-week run-in period 12-week treatment period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Patients meet follow criterion start treatment eligible study : Receiving stable treatment antihypertensive include ARB least 8 week baseline ( 0W ) . Receiving stable antidiabetic treatment with/without antidiabetic least 8 week baseline ( 0W ) . HbA1c &gt; =6.0 % , &lt; 10 % Seated office SBP 130159mmHg DBP 8099mmHg Nocturnal hypertension ( SBP &gt; =115 mmHg ) measure Home BP 5days baseline ( 0W ) . Age &gt; =20 Patients meet follow criterion eligible study : History hypersensitivity empagliflozin Breastfeeding , pregnant , possibly pregnant , plan become pregnant Treated insulin SU With renal dysfunction ( eGFR &lt; 45mL/min/1.73m2 ) With liver dysfunction ( AST ALT 3 time high reference value ) Hypotension ( systolic blood pressure &lt; 90 mmHg ) With pituitary gland dysfunction adrenal gland dysfunction Heart failure patient whose NYHA class IV Deemed ineligible study due another reason investigator History diabetic ketoacidosis diabetic come within 3 month enrollment History Acute myocardial infarction , unstable angina , cerebrovascular disease , transient ischemic attack within 3 month enrollment Patients undergone percutaneous transluminal coronary angioplasty ( PCI ) coronary artery bypass graftin ( CABG ) within 3 month enrollment Patients receive SGLT2 inhibitor within 8 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>